Streetbeat News

NTRBW

Nutriband Inc.

Industry

Biotechnology

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. The company has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. Nutriband Inc. was incorporated in 2016 and is headquartered in Orlando, Florida.

Open

1.47

Mkt cap

44M

Volume

738

High

1.47

P/E Ratio

-2.91

52-wk high

3.44

Low

1.47

Div yield

N/A

52-wk low

0.19

Nutriband Inc. reported a record revenue increase of 50.94% year-over-year for Q3 2024 and is making strategic progress towards filing an NDA for AVERSA Fentanyl in 2025.

Portfolio Pulse from

December 04, 2024 | 2:15 pm

Nutriband Inc. has received a Notice of Publication for a patent in Hong Kong for its AVERSA™ abuse deterrent transdermal technology, potentially enhancing its market position.

Portfolio Pulse from

November 27, 2024 | 12:15 pm

Nutriband Inc. has signed a commercial development and clinical supply agreement with Kindeva Drug Delivery for Aversa Fentanyl, an abuse-deterrent fentanyl patch. This agreement will enable Kindeva to develop the manufacturing process and produce clinical supplies for FDA-required studies. Aversa Fentanyl, which combines Nutriband's proprietary technology with Kindeva's FDA-approved patch system, has a potential market of $80M - $200M in annual US sales. The technology aims to improve safety while ensuring access for patients in need.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 2:21 pm

Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) has increased its existing credit line to $5 million to support the continued development and regulatory submission process for its patented lead product platform, AVERSA™ Fentanyl. The company is targeting FDA submission for AVERSA™ Fentanyl in the first half of 2024. AVERSA™ Fentanyl, which combines Nutriband’s proprietary AVERSA™ abuse-deterrent transdermal technology and Kindeva Drug Delivery’s FDA-approved transdermal fentanyl patch system, is estimated to reach peak annual US sales of $80M - $200M.

Portfolio Pulse from Happy Mohamed

July 14, 2023 | 1:21 pm

Nutriband Inc. has received a Notice of Allowance from the USPTO for its patent application covering Aversa™ abuse deterrent technology. The USPTO is expected to issue a U.S. patent after administrative processes are completed.

Portfolio Pulse from Benzinga Newsdesk

June 23, 2023 | 11:03 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.